Skip to content
Calculator
Evidence: HighPeptideFDA ApprovedHBV and HDV entry inhibitorFDA-approved 2026 · HepcludexChronic hepatitis D

Bulevirtide

A first-in-class peptide that blocks the receptor hepatitis B and D viruses use to enter liver cells

A peptide that blocks NTCP, the liver-cell receptor hepatitis B and D viruses use to get in. Approved in Europe and, since May 22, 2026, in the US as Hepcludex for chronic hepatitis D.

Manufacturer's recommended dosing (FDA label): 8.5 mg, Once daily, Subcutaneous Details ↓

Overview

What is it?

Hepatitis D occurs only alongside hepatitis B and makes the liver disease it causes worse and faster. Both viruses enter liver cells through NTCP, the sodium taurocholate co-transporting polypeptide, a bile-acid transporter. Bulevirtide, developed as myrcludex B, is a lipopeptide that binds NTCP and blocks entry; before it, interferon used off label was the only option.

In MYR301, the phase 3 trial, 150 people took 2 mg or 10 mg a day or waited 48 weeks. The combined response (HDV RNA undetectable or down at least 2 log, plus a normal ALT) occurred in 45% and 48% against 2%. The trial ran to 144 weeks and then followed people off treatment: two years after stopping, the combined response was 24% in every group, so most people relapse when it is stopped.

Combining it with peginterferon is the main attempt to make responses last. In the 90-patient MYR203 trial, 53% on 2 mg plus peginterferon had undetectable HDV RNA 24 weeks after stopping, against 7% on 2 mg alone, and a few cleared hepatitis B surface antigen. In Austria, adding peginterferon for people responding poorly to bulevirtide alone lowered HDV RNA further.

Real-world data come largely from Europe. In 244 people with compensated cirrhosis, combined response reached 54% at 96 weeks, liver stiffness fell and the risks of liver cancer and decompensation over 96 weeks were about 3%. In a French series of people waiting for a liver transplant, three improved enough to leave the list. Neither study had a randomised control group.

The US label, effective May 22, 2026, sets the adult dose at 8.5 mg once a day by injection under the skin, to be continued while it works, and its description of MYR301 calls the arm it approved 8.5 mg. Because NTCP carries bile acids, blood bile acids rise on treatment, usually without symptoms. The boxed warning is about stopping: hepatitis D and B can flare severely afterwards, especially with cirrhosis, so liver tests and viral loads need checking for at least six months.

45-48% vs 2%
Combined response at week 48
MYR301, vs delayed treatment · PMID 37345876
8.5 mg
Once-daily adult dose
Hepcludex US label 2.1
24%
Still responding 2 years after stopping
MYR301 final · PMID 41966308
Science

Mechanism of Action

Bulevirtide blocks the door that hepatitis B and D use to enter liver cells.

🚪

NTCP entry receptor

Binds the sodium taurocholate co-transporting polypeptide, the receptor both viruses use to enter hepatocytes.

🧪

Bile acids rise

NTCP also carries bile acids into the liver, so blood bile acids rise during treatment, dose-dependently and reversibly (MYR203).

⏱️

Daily injection

Half-life about 3 hours; bioavailability 57% under the skin, more than 99% protein-bound (label 12.3).

Evidence

Published Research

The studies behind bulevirtide, read from their PubMed abstracts.

Human2016

First patients: myrcludex B, peginterferon or both, 24 patients

Twenty-four people with chronic hepatitis D took myrcludex B, peginterferon or both for 24 weeks. HDV RNA fell in all groups and became undetectable in 2, 2 and 5 patients; no serious adverse events occurred.

PMID: 27132170
Human2023

MYR301: phase 3, 150 patients, week 48

Combined response at 48 weeks: 45% on 2 mg, 48% on 10 mg, 2% untreated. HDV RNA was undetectable in 12% and 20% of the dose groups, and ALT normalized in 51% and 56% against 12%.

PMID: 37345876
Human2024

MYR301 at week 96

143 of 150 patients completed 96 weeks. Responses held or improved; 43% of week-24 non-responders and 82% of partial responders reached a virologic response by week 96.

PMID: 38734383
Human2026

MYR301 final: 144 weeks, then two years off treatment

Combined response was 57%, 54% and 56% at the end of treatment and 24% in every group two years later. Serious liver events after stopping occurred in 14% and resolved in 85% of them.

PMID: 41966308
Human2024

MYR204: adding peginterferon, phase 2b, 174 patients

Twenty-four weeks after treatment ended, HDV RNA was undetectable in 46% on bulevirtide 10 mg plus peginterferon, 12% on 10 mg alone, 32% on 2 mg plus peginterferon and 17% on peginterferon alone.

PMID: 38842520
Human2025

Pooled safety: three trials, 269 patients at week 48

Raised total bile acids (20% and 17% on 2 mg and 10 mg), injection-site reactions (16% and 20%) and headache (16% and 17%) were more common than in untreated controls. No serious adverse event was related to bulevirtide.

PMID: 39648559
Human2025

MYR203: with or without peginterferon

In a 90-patient phase 2 trial, undetectable HDV RNA 24 weeks after stopping (week 72) was reached by 53% on bulevirtide 2 mg plus peginterferon, 27% on 5 mg plus peginterferon, 7% on 2 mg alone and 0% on peginterferon alone; four patients on 2 mg plus peginterferon lost hepatitis B surface antigen. Bile acid rises were dose-dependent and reversible.

PMID: 39853842
Human2025

SAVE-D: 244 patients with cirrhosis

In a European real-world study of 244 people with compensated HDV cirrhosis on 2 mg daily for a median 92 weeks, combined response was 44% at week 48 and 54% at week 96; liver stiffness and albumin improved, and the 96-week risks of new liver cancer and decompensation were 3.0% and 2.8%.

PMID: 39793613
Human2025

On the transplant waiting list

In a French retrospective study of 41 patients listed for liver transplant, 20 treated with bulevirtide had HDV RNA fall by a median 2.56 log at 48 weeks, three were removed from the list as their liver improved, and 3-month transplant-free survival was 76.9% against 36.7% in untreated patients, who were sicker at baseline.

PMID: 39960163
Human2026

Austria: response-guided add-on

In 61 patients treated for a median 29 months, combined response was 47.2% at 12 months and 42.9% at 24. Adding peginterferon in 19 non-responders lowered HDV RNA a further 1.65 log; of 10 who stopped after undetectable HDV RNA, 7 stayed undetectable through follow-up.

PMID: 41903606
Human2024

Inside the liver: 126 paired biopsies

In paired liver biopsies from three trials, intrahepatic HDV RNA fell by 0.9-1.4 log at 24 weeks and 2.2-2.7 log at 48 weeks of bulevirtide, against no change on comparators; hepatitis delta antigen-positive liver cells and inflammatory gene activity dropped sharply, while hepatitis B replication was unaffected.

PMID: 38340811
Human2026

Real-world use with a pharmacist-led programme

In 31 consecutive patients at an Italian referral centre, bulevirtide lowered HDV RNA by week 24 and improved liver tests; 43.7% had a combined response by week 60, quality of life improved, adherence was at least 90% and adverse events were mostly mild.

PMID: 42108541
Review2026

Against interferon: a network meta-analysis

A network meta-analysis of 13 studies (922 patients) found bulevirtide alone or with peginterferon suppressed HDV RNA by the end of treatment, the combination most strongly, but no regimen kept that suppression 24 or more weeks after stopping, and no treatment significantly improved liver histology.

PMID: 42057812
Dosing

Dosing Data

Hepcludex is injected under the skin once a day after reconstitution, continued for as long as it is working; the underlying hepatitis B is managed alongside it.

Prescription antiviral; stopping can cause severe hepatitis flares, so it is stopped only under specialist supervision with monitoring.
ProtocolDoseFrequencyDurationRoute
Label: chronic hepatitis D, adults without cirrhosis or with compensated cirrhosis Approved labelHepcludex (bulevirtide) for injection US prescribing information (Gilead Sciences; DailyMed set 12391cc2, effective May 22, 2026)8.5 mgOnce dailyContinued while associated with a response; optimal duration unknownSubcutaneous

Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.

Reconstitute 1 mL
Each vial is reconstituted with 1 mL of sterile water and the whole contents injected; the label's instructions for use cover preparation, and the first dose may be given under supervision.
Open Calculator →
For Buyers

What a Buyer Needs to Know

What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.

What is sold

The approved product, as its label describes it:

  • Hepcludex (bulevirtide injection): For injection: 8.5 mg as a lyophilized powder or cake, in a single-dose vial. Forms the label lists: single-dose vials.

Source: Hepcludex (bulevirtide injection) label, section 3 (DailyMed version 1, effective May 22, 2026).

Mixing a vial: a worked example

The approved product Hepcludex (bulevirtide injection) is a powder that is mixed before use, with the liquid and volume its label names. Follow the label, not a general example. Its label says: “Aseptically reconstitute HEPCLUDEX lyophilized powder or cake by adding 1 mL of Sterile Water for Injection to the HEPCLUDEX vial.”

Source: Hepcludex (bulevirtide injection) label, sections 2 and 3 (DailyMed version 1, effective May 22, 2026).

Storage before and after mixing

Before mixing or first use: “Store HEPCLUDEX vials at room temperature between 68 °F to 77 °F (20 °C to 25 °C), excursions permitted from 59 °F to 86 °F (15 °C to 30 °C).”

After mixing or first use: “Discard unused portion.”

Source: Hepcludex (bulevirtide injection) label, sections 16 and 2 (DailyMed version 1, effective May 22, 2026).

How it is taken

As the approved label gives it: Subcutaneous (Once daily; Label: chronic hepatitis D, adults without cirrhosis or with compensated cirrhosis).

Source: Manufacturer's recommended dosing (FDA label): the route and frequency of each row in Dosing Data below.

What to expect, and when

How long it stays in the body: a half-life of about 3 hours (range 2 to 6) after subcutaneous injection. After about five half-lives almost none is left.

How long the doses were given: Label: chronic hepatitis D, adults without cirrhosis or with compensated cirrhosis: Continued while associated with a response; optimal duration unknown.

When effects appear: unknown; no source on this page gives a time to effect for Bulevirtide. Results reported in the studies are under Published Research.

Source: half-life: Hepcludex prescribing information, section 12.3 (DailyMed set 12391cc2-38c2-4cf5-86d3-2be9370127fc, effective May 22, 2026; read October 2, 2026); Manufacturer's recommended dosing (FDA label), the duration of each row in Dosing Data below.

Side effects, and when to stop or get help

From the Side Effects section: Raised total bile acids in about one in five treated patients (pooled data); Injection-site reactions and headache in roughly one in six; Serious liver flares after stopping in 14% of MYR301 patients, most of which resolved. Full list and cautions ↓

Boxed warning on the label: POSTTREATMENT SEVERE ACUTE EXACERBATION OF HEPATITIS D and B.

When the label says to stop or get help:

  • Hypersensitivity Reactions Including Anaphylaxis: Hypersensitivity reactions have been reported with HEPCLUDEX. If signs or symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue HEPCLUDEX and initiate appropriate treatment.

Source: Hepcludex (bulevirtide injection) label, boxed warning and section 5 (DailyMed version 1, effective May 22, 2026); the Side Effects section below (“From the studies above”).

Interactions

  • pravastatin (OATP1B1 substrate): at high-dose bulevirtide steady state, pravastatin AUC rose 1.32-fold
  • tenofovir disoproxil: no relevant change in tenofovir pharmacokinetics; CYP3A activity fell 29% during combination; plasma bile acids rose 19-fold

Every peptide's record, with its source: the interaction matrix.

Source: human study, PMID 28543042; human study, PMID 37089922.

Checking what you bought

Unknown: no published independent test of Bulevirtide products is in our lab-results database yet, so how products sold under this name measure up is not known.

To read a certificate of analysis, paste it into the COA decoder; it checks the measured mass against Bulevirtide's expected mass, 5,399.0 Da, from this entry's molecular data. Trust & Verification explains what independent testing can and cannot show.

Legal status

US: FDA Approved (Approved in the US as Hepcludex (bulevirtide), BLA 761468, on May 22, 2026, for chronic hepatitis D virus infection in adults without cirrhosis or with compensated cirrhosis (Drugs@FDA via openFDA and the Hepcludex label, read October 2, 2026)). Sport: Not on the 2026 List.

Country by country ↓ · Regulatory tracker

Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.

Safety

Side Effects & Contraindications

Reported Side Effects

From the studies above.

● Raised total bile acids in about one in five treated patients (pooled data)
● Injection-site reactions and headache in roughly one in six
● Serious liver flares after stopping in 14% of MYR301 patients, most of which resolved

Contraindications & Cautions

From the Hepcludex label (DailyMed, effective May 22, 2026).

● Boxed warning: severe flares of hepatitis D and B after treatment stops, especially with cirrhosis
● Hypersensitivity reactions, including anaphylaxis
● Not evaluated in end-stage kidney disease or dialysis
● Tested athletes — see the Sport (WADA) row below
Questions

Frequently Asked Questions

?What is bulevirtide?

A first-in-class peptide that blocks NTCP, the receptor hepatitis B and D viruses use to enter liver cells. It is sold as Hepcludex for chronic hepatitis D.

?Is bulevirtide FDA-approved?

Yes. The FDA approved Hepcludex on May 22, 2026, for adults with chronic hepatitis D without cirrhosis or with compensated cirrhosis. It was already approved in Europe.

?Does it cure hepatitis D?

Not reliably. In MYR301 the combined response was 54% to 57% at the end of 144 weeks of treatment but fell to 24% two years after stopping, and the label warns of severe flares after stopping.

?Why does it raise bile acids?

Its target, NTCP, is the liver's bile-acid uptake transporter. Blocking it to keep the virus out also keeps some bile acids in the blood; in trials the rise was dose-dependent and reversed after treatment.

?Is it combined with interferon?

Not in the US label. In the MYR203 trial, adding peginterferon gave more lasting responses (53% undetectable 24 weeks after stopping, against 7% on bulevirtide alone), and some European centres add it for poor responders.

Bibliography

References

  1. [fda] US FDA, Drugs@FDA (openFDA): HEPCLUDEX (bulevirtide), BLA 761468, original approval May 22, 2026, prescription. Read October 2, 2026.
  2. [fda-pi] FDA. Hepcludex (bulevirtide) US prescribing information (DailyMed set 12391cc2-38c2-4cf5-86d3-2be9370127fc, version 1, effective May 22, 2026). Read October 2, 2026.
  3. [clinical-trial] Bogomolov P, et al. "Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study." J Hepatol, 2016;65(3):490-8. PMID: 27132170.
  4. [clinical-trial] Wedemeyer H, et al. "A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D." N Engl J Med, 2023;389(1):22-32. PMID: 37345876.
  5. [clinical-trial] Wedemeyer H, et al. "Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial." J Hepatol, 2024;81(4):621-629. PMID: 38734383.
  6. [clinical-trial] Wedemeyer H, et al. "144 Weeks of bulevirtide monotherapy for chronic hepatitis D: Final and post-treatment results from a phase III randomized trial." J Hepatol, 2026;85(3):493-503. PMID: 41966308.
  7. [clinical-trial] Asselah T, et al. "Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D." N Engl J Med, 2024;391(2):133-143. PMID: 38842520.
  8. [pubmed] Asselah T, et al. "Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48." Liver Int, 2025;45(4):e16174. PMID: 39648559.
  9. [clinical-trial] Lampertico P, et al. "Phase 2 Randomised Study of Bulevirtide as Monotherapy or Combined With Peg-IFNα-2a as Treatment for Chronic Hepatitis Delta." Liver Int, 2025;45(2):e70008. PMID: 39853842.
  10. [pubmed] Degasperi E, et al. "Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis." J Hepatol, 2025;82(6):1012-1022. PMID: 39793613.
  11. [pubmed] Meszaros M, et al. "Bulevirtide in Chronic Hepatitis D Patients Awaiting Liver Transplantation Results From a French Multicentric Retrospective Study." Liver Int, 2025;45(3):e70033. PMID: 39960163.
  12. [pubmed] Schwarz M, et al. "Response-guided bulevirtide ± pegylated interferon alfa-2a: Long-term outcomes observed in the nationwide Austrian hepatitis D cohort study." JHEP Rep, 2026;8(6):101835. PMID: 41903606.
  13. [fda-pi] Hepcludex (bulevirtide) for injection US prescribing information (Gilead Sciences; DailyMed set 12391cc2, version 1, effective May 22, 2026), sections 2.1, 5.1 and 12.3 and boxed warning; read through openFDA October 6, 2026.
  14. [pubmed] Allweiss L, et al. "Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies." J Hepatol, 2024;80(6):882-891. PMID: 38340811.
  15. [pubmed] Karkra R, et al. "Comparative Efficacy of Bulevirtide, Interferons, and Nucleos(t)ide Analogs for Chronic Hepatitis Delta: A Systematic Review and Network Meta-Analysis." Int J Hepatol, 2026;2026:6325996. PMID: 42057812.
  16. [pubmed] Mengato D, et al. "Effectiveness, Safety and Patient-Reported Outcomes of Bulevirtide Therapy in Chronic Hepatitis Delta: Real-World Evidence From a Prospective Observational Study." J Viral Hepat, 2026;33(6):e70181. PMID: 42108541.

Sources & Citations

Studies were read from their PubMed abstracts; the label from DailyMed (set 12391cc2, effective May 22, 2026) through openFDA, read October 6, 2026.

Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.

Last reviewed: 2026-10-16